To date, this lack of consistency between the results of the studies referred above implies that the assessment of the role of NPY levels as a possible marker of active disease in RA patients should be assessed in studies with a multivariate approach controlling potential confounders including the serum levels of other proinflammatory cytokines and leptin. The gene discussed is NPY; the disease is rheumatoid arthritis.